Efficacy of gefitinib as a first-line single agent treatment in patients with advanced non-small cell lung cancer

查看全文 作　　者：Yongmei Yin Yiting Geng Xiaodong Li Xiaoli Hu Xiaofeng Chen Wei Li Yongqian [1]Shu

机构地区：[1]Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China

出　　处：《Journal of Nanjing Medical University》索引2009年第23卷第6期,共6页

基　　金：supported by grants from the Jiangsu Provincial Natural Science Foundation (BK2008477);the Department of Health of Jiangsu Province Open Foundation (XK.18200904) 摘　　要：Objective: To assess the efficacy and toxicity of gefitinib as a single agent treatment in Chinese patients with advanced non-small cell lung cancer (NSCLC). Methods: Forty-five patients with advanced NSCLC were treated with gefitinib at 250 mg daily until the disease progressed or the patient could not tolerate the toxicity. Results: None of the patients achieved a complete response (CR), while 15 patients achieved a partial remission (PR) and 17 experienced a stable disease (SD). Thirteen patients continued to have a progressive disease (PD). The response rate and the disease control rate were 33.3% and 71.1%, respectively. The symptom remission rate was 72.5%, and the median remission time was 8 days. The median survival time was 15.3 months. The median progression-free survival time was 6.0 months. The most common toxicities included rash (53.3%) and diarrhea (33.3%). Dehydration and pruritus of the skin developed in 26.7% and 22.2% of the patients, respectively. Hepatic toxicity occurred in 6.7% of patients and oral ulceration occurred in 4.4% of patients. Conclusion: Single agent treatment with gefitinib is effective against advanced NSCLC, and is well tolerated in Chinese patients. 关键词：治疗肺癌细胞单剂晚期生存时间肝毒性不良反应

相关文献

参考文献（10）
引证文献（1）
耦合文献（0）

参考文献(10)

引证文献(1)

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

Efficacy of gefitinib as a first-line single agent treatment in patients with advanced non-small cell lung cancer

参考文献(10)

引证文献(1)

用户提示